These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26837935)

  • 1. Critical appraisal of selegiline transdermal system for major depressive disorder.
    Cristancho MA; Thase ME
    Expert Opin Drug Deliv; 2016; 13(5):659-65. PubMed ID: 26837935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
    Patkar AA; Pae CU; Masand PS
    CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
    Robinson DS; Amsterdam JD
    J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical appraisal of the selegiline transdermal system for major depressive disorder.
    Bied AM; Kim J; Schwartz TL
    Expert Rev Clin Pharmacol; 2015; 8(6):673-81. PubMed ID: 26427518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
    Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS
    J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine oxidase inhibitors: a new generation.
    Robinson DS
    Psychopharmacol Bull; 2002; 36(3):124-38. PubMed ID: 12473970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline transdermal system: current awareness and promise.
    Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal selegiline in patients receiving electroconvulsive therapy.
    Horn PJ; Reti I; Jayaram G
    Psychosomatics; 2010; 51(2):176-8. PubMed ID: 20332294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal selegiline.
    Patkar AA; Pae CU; Zarzar M
    Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
    Amsterdam JD
    J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).
    Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA
    J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline transdermal system: a novel treatment option for major depressive disorder.
    Nandagopal JJ; DelBello MP
    Expert Opin Pharmacother; 2009 Jul; 10(10):1665-73. PubMed ID: 19527191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
    Bodkin JA; Amsterdam JD
    Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
    Robinson DS; Gilmor ML; Yang Y; Moonsammy G; Azzaro AJ; Oren DA; Campbell BJ
    Psychopharmacol Bull; 2007; 40(3):15-28. PubMed ID: 18007565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translating the evidence on atypical depression into clinical practice.
    Hyman Rapaport M
    J Clin Psychiatry; 2007; 68 Suppl 3():31-6. PubMed ID: 17348765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
    Tobin M
    Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
    [No Abstract]   [Full Text] [Related]  

  • 18. MAOIs and transdermal delivery.
    Vandenberg CM
    J Clin Psychiatry; 2012 Sep; 73(9):e28. PubMed ID: 23059160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
    Thomas SJ; Shin M; McInnis MG; Bostwick JR
    Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of monoamine oxidase inhibitors in depression treatment guidelines.
    Thase ME
    J Clin Psychiatry; 2012; 73 Suppl 1():10-6. PubMed ID: 22951237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.